Work

A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy

Year: 2024

Type: article

Abstract: Tirzepatide, a novel long-acting glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 (GIP/GLP-1) receptor agonist (GIP/GLP-1 RA), has shown greater clinical efficacy in reducing HbA1c and body weight compared with placebo or selective GLP-1 RAs.1, 2 Mechanisms by which GLP-1R agonism contributes to chronic weight management and glycaemia are well understood. The contributions of GIPR agonism to the clinical efficacy of tirzepatide are less well known.

Source: Diabetes Obesity and Metabolism

DOI: 10.1111/dom.15875